Ventyx Biosciences

VTYX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Ventyx Biosciences, Inc. (NasdaqGS: VTYX) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Ventyx will receive $14.00 in cash for each share of Ventyx that they own. KSF is seeking to determine whether this consideration and the process that led to i.

NEW YORK and NEW ORLEANS, Jan. 23, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Shareholders should contact the firm as there may be limited time to enforce your rights. Shareholders should contact the firm as there may be limited time to enforce your rights.

NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK and NEW ORLEANS, Jan. 8, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

NEWTOWN, Pa., Jan. 8, 2026 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Ventyx Biosciences, Inc. ("Ventyx") (NASDAQ: VTYX), resulting from allegations of providing potentially misleading business information to the investing public.

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - January 8, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Eli Lilly and Company (NYSE: LLY) for $14.00 per share of common stock in an all-cash transaction (equal to an aggregate equity value of approximately $1.2 billion). The investigation concerns whether the Ventyx Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders.

Michael Yee, global head of biotech research at UBS, joins CNBC's ‘Squawk on the Street' to explain why he is bullish on biopharma stocks this year, the pharma M&A outlook, and more.

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.